Unresectable Melanoma Active Not Recruiting Phase 2 Trials for DB06589 (Pazopanib)

IndicationStatusPhase
DBCOND0047213 (Unresectable Melanoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01107665Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV MelanomaTreatment